Healthcare
Live Price
Offline$7.12
+14.29% today
1Y Change
-44.55%
Window
Jun 23, 2025 → Jun 18, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Predictive Oncology Inc. (POAI) is a Healthcare stock with a market cap of $20.00M and listed on NASDAQ. The stock last traded around $7.12 and down 44.5% across the available one-year price window (Jun 23, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of -92.3%, EPS growth of -496.9%, a dividend yield of 0.0%. What stands out right now is revenue -92.3%, EPS -496.9%, free cash flow +16.8% with operating margin -22688.6% and ROIC -57.6%. Valuation already assumes a fairly strong business story at price/sales 149.5. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines POAI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
POAI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
POAI Max Drawdown
-92.17%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for POAI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.4M
-5.6% YoY
FY Net Income
-$19.7M
+23.6% YoY
Free Cash Flow
-$13.2M
-2.5% YoY
Revenue Growth
-92.3%
EPS Growth
-496.9%
Gross Margin
42.0%
Net Margin
-186053.4%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 125K | 2M | 2M | 2M | 1M |
| Gross Profit | 53K | 798K | 1M | 1M | 934K |
| Operating Income | -233M | -11M | -12M | -26M | -20M |
| EBITDA | -233M | -10M | -12M | -14M | -12M |
| Net Income | -233M | -12M | -14M | -26M | -20M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 11M | 735K | 9M | 22M | 28M |
| Total Assets | 53M | 5M | 14M | 26M | 44M |
| Total Liabilities | 5M | 5M | 6M | 4M | 4M |
| Shareholder Equity | 48M | -203K | 8M | 22M | 40M |
| Total Debt | 2M | 2M | 3M | 180K | 879K |
| Net Debt | -9M | 1M | -6M | -22M | -27M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
12M
+1.3% YoY
Capital Expenditures
962K
-102.3% YoY
Free Cash Flow
13M
-2.5% YoY
Key ratios
Gross Margin
42.0%
Operating Margin
-22688.6%
Net Margin
-186053.4%
ROE
2959.0%
Debt / Equity
0.03x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.